Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$59.88 USD
+1.18 (2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $59.85 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Brokerage Reports
Praxis Precision Medicines, Inc. [PRAX]
Reports for Purchase
Showing records 1 - 20 ( 110 total )
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
A Chance to Resize Bolsters Confidence in Essential3 Readout; Price Target Up to $120
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Essential3 Interim Expected Before Main Data, As Epilepsy Programs Advance
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
ET KOL Check: Delving Into The Therapeutic Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
INVITE: ET KOL Call - Delving Into The Therapeutic Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
All That JAZZ --- Thoughts on Suvecaltamide, PRAX/ Ulixacaltamide
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Top 16 Takeaways From Our Coverage at the H.C. Wainwright Bioconnect Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Ulixacaltimide Nears Readout, Epilepsy Portfolio Advances; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to Essential3 Data in 2H24 [1Q24 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from Our Call with Praxis Management; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Lighting Things Up With PRAX-628, But We''re Waiting For P2b Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Today''s Data Offers a Strong Early Signal of PRAX-628''s Blockbuster Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
After a Productive 2023, 2024 Should Be a Banner Year for Praxis
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
PPR Update Comes Next (1Q24), As ET Efforts Progress
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary PPR Results For 15mg Cohort Provide a Win; What We''re Looking for Next
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Praxis Precision Medicines, Inc.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department